Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMLX vs $OGN | Chartloom

Compare

$AMLX vs $OGN

Amylyx Pharmaceuticals Inc · Organon & Co

AMLX

Amylyx Pharmaceuticals Inc

OGN

Organon & Co

Compare $AMLX vs $OGN

Comparing Amylyx Pharmaceuticals Inc and Organon & Co

AMLXAmylyx Pharmaceuticals Inc

OGNOrganon & Co

AMLXAmylyx Pharmaceuticals Inc

Market cap

$2.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

135.1%

52W performance

88.3%

FCF yield

-4.2%

OGNOrganon & Co

Market cap

$3.62B

P/E (TTM)

17.82x

Forward P/E (NTM)

3.84x

Forward P/S (NTM)

0.58x

Rev growth (TTM)

-2.5%

YTD performance

90.2%

52W performance

43.4%

FCF yield

12.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMLX

OGN

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

OGN

Organon & Co

Market Cap

AMLX$2.99B

OGN$3.62B

Enterprise Value

AMLX$2.94B

OGN$11.04B

Price

AMLX$26.85

OGN$13.77

P/E Ratio

AMLXN/A

OGN17.82x

P/S Ratio

AMLX17.98x

OGN0.59x

EV/Sales

AMLX17.63x

OGN1.80x

EV/EBITDA

AMLX87.31x

OGN6.50x

P/B Ratio

AMLX14.77x

OGN3.61x

P/FCF Ratio

AMLXN/A

OGN8.33x

EV/FCF

AMLX-23.17x

OGN25.43x

PEG Ratio

AMLXN/A

OGNN/A

Forward P/E (NTM)

AMLXN/A

OGN3.84x

Forward P/S (NTM)

AMLXN/A

OGN0.58x

Revenue (TTM)

AMLX$0

OGN$6.13B

Revenue Growth (YoY)

AMLX-100.0%

OGN-2.5%

Forward Rev Growth

AMLX195.4%

OGN1.6%

Gross Margin (TTM)

AMLX82.8%

OGN52.7%

Operating Margin (TTM)

AMLX0.0%

OGN8.0%

EBITDA Margin (TTM)

AMLX0.0%

OGN27.7%

Net Margin (TTM)

AMLX0.0%

OGN3.4%

FCF Margin (TTM)

AMLXN/A

OGN7.1%

Net Income (TTM)

AMLX$-152M

OGN$209M

FCF (TTM)

AMLX$-127M

OGN$434M

EPS (TTM)

AMLX-$1.37

OGN$0.77

ROE (TTM)

AMLX-5292.0%

OGN23.4%

ROA (TTM)

AMLX-4853.0%

OGN1.6%

ROIC (TTM)

AMLX-5292.0%

OGN2.2%

Cash

AMLX$49M

OGN$1.13B

Debt

AMLX$0

OGN$8.55B

Net Cash/Debt

AMLX$49M

OGN$-7.42B

Current Ratio (TTM)

AMLX12.12x

OGN1.95x

Quick Ratio (TTM)

AMLX11.86x

OGN1.44x

Debt/Equity (TTM)

AMLX0.00x

OGN8.50x

Debt/Assets (TTM)

AMLX0.0%

OGN0.0%

Interest Coverage (TTM)

AMLXN/A

OGNN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

OGN0.00x

Beta

AMLX-0.10

OGN1.50

52W Performance

AMLX88.3%

OGN43.4%

YTD Performance

AMLX135.1%

OGN90.2%

% from 52W High

AMLX-34.7%

OGN-0.7%

% from 52W Low

AMLX147.9%

OGN142.0%

Asset Turnover (TTM)

AMLX0.50x

OGN0.47x

FCF Yield (TTM)

AMLX-4.2%

OGN12.0%

Earnings Yield (TTM)

AMLX-5.1%

OGN5.8%

Dividend Yield (TTM)

AMLXN/A

OGN0.5%

Rule of 40

AMLX-100.0

OGN4.6

EV/GP/RG

AMLXN/A

OGN2.99

Ticker research

View AMLX research View OGN research

Metric	AMLX Amylyx Pharmaceuticals Inc	OGN Organon & Co
Market & Valuation
Market Cap	$2.99B	$3.62B
Enterprise Value	$2.94B	$11.04B
Price	$26.85	$13.77
P/E Ratio	N/A	17.82x
P/S Ratio	17.98x	0.59x
EV/Sales	17.63x	1.80x
EV/EBITDA	87.31x	6.50x
P/B Ratio	14.77x	3.61x
P/FCF Ratio	N/A	8.33x
EV/FCF	-23.17x	25.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	3.84x
Forward P/S (NTM)	N/A	0.58x
Revenue & Growth
Revenue (TTM)	$0	$6.13B
Revenue Growth (YoY)	-100.0%	-2.5%
Forward Rev Growth	195.4%	1.6%
Profitability
Gross Margin (TTM)	82.8%	52.7%
Operating Margin (TTM)	0.0%	8.0%
EBITDA Margin (TTM)	0.0%	27.7%
Net Margin (TTM)	0.0%	3.4%
FCF Margin (TTM)	N/A	7.1%
Net Income (TTM)	$-152M	$209M
FCF (TTM)	$-127M	$434M
EPS (TTM)	-$1.37	$0.77
ROE (TTM)	-5292.0%	23.4%
ROA (TTM)	-4853.0%	1.6%
ROIC (TTM)	-5292.0%	2.2%
Financial Health
Cash	$49M	$1.13B
Debt	$0	$8.55B
Net Cash/Debt	$49M	$-7.42B
Current Ratio (TTM)	12.12x	1.95x
Quick Ratio (TTM)	11.86x	1.44x
Debt/Equity (TTM)	0.00x	8.50x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	1.50
52W Performance	88.3%	43.4%
YTD Performance	135.1%	90.2%
% from 52W High	-34.7%	-0.7%
% from 52W Low	147.9%	142.0%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.47x
FCF Yield (TTM)	-4.2%	12.0%
Earnings Yield (TTM)	-5.1%	5.8%
Dividend Yield (TTM)	N/A	0.5%
Other
Rule of 40	-100.0	4.6
EV/GP/RG	N/A	2.99
Ticker research	View AMLX research	View OGN research

Valuation

P/E Ratio

OGN

17.82x

P/S Ratio

OGN

0.59x

AMLX

17.98x

EV/FCF

AMLX

-23.17x

OGN

25.43x

Growth & revenue

Revenue Growth TTM

OGN

-2.5%

AMLX

-100.0%

Forward Revenue Growth

AMLX

195.4%

OGN

1.6%

Profitability & performance

Gross Margin

AMLX

82.8%

OGN

52.7%

ROE

OGN

23.4%

AMLX

-5292.0%

FCF Yield %

OGN

12.0%

AMLX

-4.2%

52-Week Performance

AMLX

88.3%

OGN

43.4%

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

OGN

Organon & Co

Market Cap

AMLX$2.99B

OGN$3.62B

Enterprise Value

AMLX$2.94B

OGN$11.04B

Price

AMLX$26.85

OGN$13.77

P/E Ratio

AMLXN/A

OGN17.82x

P/S Ratio

AMLX17.98x

OGN0.59x

EV/Sales

AMLX17.63x

OGN1.80x

EV/EBITDA

AMLX87.31x

OGN6.50x

P/B Ratio

AMLX14.77x

OGN3.61x

P/FCF Ratio

AMLXN/A

OGN8.33x

EV/FCF

AMLX-23.17x

OGN25.43x

PEG Ratio

AMLXN/A

OGNN/A

Forward P/E (NTM)

AMLXN/A

OGN3.84x

Forward P/S (NTM)

AMLXN/A

OGN0.58x

Revenue (TTM)

AMLX$0

OGN$6.13B

Revenue Growth (YoY)

AMLX-100.0%

OGN-2.5%

Forward Rev Growth

AMLX195.4%

OGN1.6%

Gross Margin (TTM)

AMLX82.8%

OGN52.7%

Operating Margin (TTM)

AMLX0.0%

OGN8.0%

EBITDA Margin (TTM)

AMLX0.0%

OGN27.7%

Net Margin (TTM)

AMLX0.0%

OGN3.4%

FCF Margin (TTM)

AMLXN/A

OGN7.1%

Net Income (TTM)

AMLX$-152M

OGN$209M

FCF (TTM)

AMLX$-127M

OGN$434M

EPS (TTM)

AMLX-$1.37

OGN$0.77

ROE (TTM)

AMLX-5292.0%

OGN23.4%

ROA (TTM)

AMLX-4853.0%

OGN1.6%

ROIC (TTM)

AMLX-5292.0%

OGN2.2%

Cash

AMLX$49M

OGN$1.13B

Debt

AMLX$0

OGN$8.55B

Net Cash/Debt

AMLX$49M

OGN$-7.42B

Current Ratio (TTM)

AMLX12.12x

OGN1.95x

Quick Ratio (TTM)

AMLX11.86x

OGN1.44x

Debt/Equity (TTM)

AMLX0.00x

OGN8.50x

Debt/Assets (TTM)

AMLX0.0%

OGN0.0%

Interest Coverage (TTM)

AMLXN/A

OGNN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

OGN0.00x

Beta

AMLX-0.10

OGN1.50

52W Performance

AMLX88.3%

OGN43.4%

YTD Performance

AMLX135.1%

OGN90.2%

% from 52W High

AMLX-34.7%

OGN-0.7%

% from 52W Low

AMLX147.9%

OGN142.0%

Asset Turnover (TTM)

AMLX0.50x

OGN0.47x

FCF Yield (TTM)

AMLX-4.2%

OGN12.0%

Earnings Yield (TTM)

AMLX-5.1%

OGN5.8%

Dividend Yield (TTM)

AMLXN/A

OGN0.5%

Rule of 40

AMLX-100.0

OGN4.6

EV/GP/RG

AMLXN/A

OGN2.99

Ticker research

View AMLX research View OGN research

Metric	AMLX Amylyx Pharmaceuticals Inc	OGN Organon & Co
Market & Valuation
Market Cap	$2.99B	$3.62B
Enterprise Value	$2.94B	$11.04B
Price	$26.85	$13.77
P/E Ratio	N/A	17.82x
P/S Ratio	17.98x	0.59x
EV/Sales	17.63x	1.80x
EV/EBITDA	87.31x	6.50x
P/B Ratio	14.77x	3.61x
P/FCF Ratio	N/A	8.33x
EV/FCF	-23.17x	25.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	3.84x
Forward P/S (NTM)	N/A	0.58x
Revenue & Growth
Revenue (TTM)	$0	$6.13B
Revenue Growth (YoY)	-100.0%	-2.5%
Forward Rev Growth	195.4%	1.6%
Profitability
Gross Margin (TTM)	82.8%	52.7%
Operating Margin (TTM)	0.0%	8.0%
EBITDA Margin (TTM)	0.0%	27.7%
Net Margin (TTM)	0.0%	3.4%
FCF Margin (TTM)	N/A	7.1%
Net Income (TTM)	$-152M	$209M
FCF (TTM)	$-127M	$434M
EPS (TTM)	-$1.37	$0.77
ROE (TTM)	-5292.0%	23.4%
ROA (TTM)	-4853.0%	1.6%
ROIC (TTM)	-5292.0%	2.2%
Financial Health
Cash	$49M	$1.13B
Debt	$0	$8.55B
Net Cash/Debt	$49M	$-7.42B
Current Ratio (TTM)	12.12x	1.95x
Quick Ratio (TTM)	11.86x	1.44x
Debt/Equity (TTM)	0.00x	8.50x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	1.50
52W Performance	88.3%	43.4%
YTD Performance	135.1%	90.2%
% from 52W High	-34.7%	-0.7%
% from 52W Low	147.9%	142.0%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.47x
FCF Yield (TTM)	-4.2%	12.0%
Earnings Yield (TTM)	-5.1%	5.8%
Dividend Yield (TTM)	N/A	0.5%
Other
Rule of 40	-100.0	4.6
EV/GP/RG	N/A	2.99
Ticker research	View AMLX research	View OGN research